Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Ketamine for Prevention of Depression in Cancer Patients
NCT02442739Phase 1Withdrawn
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Aug 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing Ketamine with Placebo (2 arms). Primary endpoints: Proportion of patients pre-screened that were potentially eligible for study participation at 36 months, Proportion of patients that were potentially eligible who were approached at 36 months and 5 more. Planned start Aug 2016; status: withdrawn.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02442739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02442739.